Company Overview and News

 
Anglo American expresses support for NSW Govt’s Drayton South renewal

2017-12-03 australianmining.com.au
Anglo American has expressed support for the New South Wales Government’s decision to renew operations at the Drayton South coal mine. The NSW Government resources minister Don Harwin approved underground operations at the contentious coal mine last Friday (December 1).

 
Going underground: coal miner hopes switch will help project clear objections

2017-12-01 theage.com.au
The Berejiklian government has renewed the exploration licence to develop a coal reserve in the Hunter Valley for a site that had been knocked back four times by the independent Planning Assessment Commission.

 
Going underground: coal miner hopes switch will help project clear objections

2017-12-01 smh.com.au
The Berejiklian government has renewed the exploration licence to develop a coal reserve in the Hunter Valley for a site that had been knocked back four times by the independent Planning Assessment Commission.

 
Australia to pay China's Shenhua $200 million to buy back mining licence

2017-07-12 in.reuters
SYDNEY (Reuters) - Australia's New South Wales state said on Wednesday it would buy back half of a coal exploration licence from China Shenhua Energy Co Ltd, bowing to pressure from farmers and environmentalists opposed to mining on prime agricultural land.

 
Mine’s sale is up and racing

2017-05-04 perthnow.com.au
A MAJOR coal project that sparked long-running controversy over its proximity to Australia’s top horse studs has been sold — and its buyer guaranteed it would only mine underground, away from thoroughbred businesses.

 
Sale of Drayton coal mine

2017-05-04 londonstockexchange
Anglo American plc ("Anglo American") announces that it has entered into a Sale and Purchase Agreement with Malabar Coal Limited to sell its 88.17% interest in the Drayton thermal coal mine and Drayton South project (together, "Drayton"), located in New South Wales, Australia (the "Transaction"). 

 
Malabar Coal Ltd to conduct institutional and retail raising

2016-08-31 proactiveinvestors.com.au
Malabar Coal Ltd (ASX:MBC) is focused on the established coal fields of the Upper Hunter Valley in New South Wales.

 
 
 
Director Appointment Morgan

2016-04-19 asx.com.au

 

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...